Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 7, 2014; 20(5): 1228-1237
Published online Feb 7, 2014. doi: 10.3748/wjg.v20.i5.1228
Inflammatory bowel disease: An increased risk factor for neurologic complications
Germán Morís
Germán Morís, Neurology Department, Hospital Universitario Central Asturias, Oviedo, 33006 Asturias, Spain
Author contributions: Morís G contributed to this work with conception and design, acquisition of data and interpretation of data; Morís G drafted the article and final approved of the version to be published.
Correspondence to: Germán Morís, MD, Neurology Department, Hospital Universitario Central Asturias, C/Celestino Villamil s/n, Oviedo, 33006 Asturias, Spain. gmorist@gmail.com
Telephone: +34-98-5108000 Fax: +34-98-5109479
Received: October 10, 2013
Revised: December 21, 2013
Accepted: January 3, 2014
Published online: February 7, 2014
Processing time: 132 Days and 22.5 Hours
Abstract

Only a very few systematic studies have investigated the frequency of neurologic disorders in patients with Crohn’s disease (CD) and ulcerative colitis (UC), which are the two main types of inflammatory bowel disease (IBD). Results have been inconsistent and variable, owing to differences in case-finding methods and evaluated outcomes in different studies. The most frequent neurologic manifestations reported in CD and UC populations are cerebrovascular disease (with either arterial or venous events), demyelinating central nervous system disease, and peripheral neuropathy (whether axonal or demyelinating); however, the literature describes numerous nervous system disorders as being associated with IBD. The pathogenesis of nervous system tissue involvement in IBD has yet to be elucidated, although it seems to be related to immune mechanisms or prothrombotic states. The recently-introduced tumor necrosis factor (TNF) inhibitors have proven successful in controlling moderate to severe IBD activity. However, severe neurologic disorders associated with TNF inhibitors have been reported, which therefore raises concerns regarding the effect of anti-TNF-α antibodies on the nervous system. Although neurological involvement associated with IBD is rarely reported, gastroenterologists should be aware of the neurologic manifestations of IBD in order to provide early treatment, which is crucial for preventing major neurologic morbidity.

Keywords: Extraintestinal manifestations; Inflammatory bowel disease; Multiple sclerosis; Neuropathy; Stroke; Tumor necrosis factor inhibitor

Core tip: The neurological manifestations in inflammatory bowel disease (IBD) patients are often unrecognized or underestimated. A detailed revision of the literature about the neurological manifestations in ulcerative colitis and Crohn’s disease patients is relevant to the IBD community, especially in the biologics era. Gastroenterologists should be aware of the neurologic manifestations of IBD in order to provide prevention and early treatment, which is crucial for preventing major neurologic morbidity.